These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 27872452)

  • 21. Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Lionaki S; Fragoulis GE; Venetsanopoulou A; Vlachoyiannopoulos P; Boletis JN; Tzioufas AG
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):155-164. PubMed ID: 28134075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.
    Yates M; Watts RA; Bajema IM; Cid MC; Crestani B; Hauser T; Hellmich B; Holle JU; Laudien M; Little MA; Luqmani RA; Mahr A; Merkel PA; Mills J; Mooney J; Segelmark M; Tesar V; Westman K; Vaglio A; Yalçındağ N; Jayne DR; Mukhtyar C
    Ann Rheum Dis; 2016 Sep; 75(9):1583-94. PubMed ID: 27338776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
    Timlin H; Lee SM; Manno RL; Seo P; Geetha D
    Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How to treat ANCA‑associated vasculitis: practical messages from 2016 EULAR/ERA‑EDTA recommendations.
    Sznajd J; Mukhtyar C
    Pol Arch Med Wewn; 2016 Oct; 126(10):781-788. PubMed ID: 27872452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [De-escalation of therapy in ANCA-associated vasculitides].
    Schinke S; Riemekasten G; Lamprecht P
    Z Rheumatol; 2017 Feb; 76(1):15-20. PubMed ID: 27933390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Current guidelines on ANCA-associated vasculitides : Common features and differences].
    Hellmich B
    Z Rheumatol; 2017 Mar; 76(2):133-142. PubMed ID: 27848024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
    Jones RB
    Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides.
    McGeoch L; Twilt M; Famorca L; Bakowsky V; Barra L; Benseler SM; Cabral DA; Carette S; Cox GP; Dhindsa N; Dipchand CS; Fifi-Mah A; Goulet M; Khalidi N; Khraishi MM; Liang P; Milman N; Pineau CA; Reich HN; Samadi N; Shojania K; Taylor-Gjevre R; Towheed TE; Trudeau J; Walsh M; Yacyshyn E; Pagnoux C;
    J Rheumatol; 2016 Jan; 43(1):97-120. PubMed ID: 26523024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
    Rich EN; Brown KK
    Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab for ANCA-associated vasculitides.
    Guillevin L
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S118-21. PubMed ID: 24854382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).
    Daikeler T; Kistler AD; Martin PY; Vogt B; Huynh-Do U
    Swiss Med Wkly; 2015; 145():w14103. PubMed ID: 25658140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conventional induction and maintenance treatment of Antineutrophil cytoplasmic antibodies-associated vasculitis - still of value for our patients?
    Tesar V; Hruskova Z
    Expert Opin Pharmacother; 2015; 16(11):1683-702. PubMed ID: 26149512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment strategies for ANCA-associated vasculitides].
    Hellmich B
    Z Rheumatol; 2015 Jun; 74(5):388-97. PubMed ID: 26031284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-cell-targeted therapy in systemic vasculitis.
    Lally L; Spiera R
    Curr Opin Rheumatol; 2016 Jan; 28(1):15-20. PubMed ID: 26599379
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.